Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 379

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 379
---
to -enddata. Market Opportunity To achieve our long -termobjectives, we intend to build and consolidate our market position for our core product categories by continuing to validate their individual strengths in the marketplace. Further, there is potential for collaboration with healthcare providers and platforms, diagnostic laboratories, researchers, self -insuredemployers, payers, insurance companies and pharmaceutical companies. As Latin America is an underserved market with growing population, through our products, we plan on expanding our presence in the region by increasing the market penetration of our offering in the region. This expansion includes scaling Rewell and Heritas throughout Latin America, entering both (i) mature markets, such as Argentina, Mexico, Brazil, Colombia, Chile and Uruguay, and (ii) emerging markets, such as those in Central America, Peru, Ecuador, Paraguay, Bolivia and Venezuela, in respect of the precision medicine industry. 189 Rewell: Wellness & Prevention Rewell offers a comprehensive suite of prevention solutions, including DNA and microbiome kits, as well as the potential introduction of nutrigenetic programs. Our growth strategy focuses on expanding through both business -to -businessdistribution, such as targeting select laboratories and nutrition centers, and direct -to -consumerchannels. We plan to provide our customers with continuous updates on their DNA information as we develop Rewell. Microbiome analyses, a key component of Rewell, represent a significant and expanding market opportunity. With growing public and scientific interest in the link between the microbiome and overall health, Rewell is positioned to uncover the vital role the human microbiome plays in immunity, digestion, and even mental health. As such, we anticipate increased consumer demand for personalized health information based on microbiome analysis. We will continue to invest in Rewell, establishing the brand as a provider of premier preventive health solutions that incorporates DNA and microbiome insights into lifestyle choices. We expect Rewell to be positioned within the elite of the sports and healthcare industries by leveraging partnerships with select laboratories, nutrition centers, and key sports and health influencers. These partnerships will be crucial to increase the brand’s visibility, a key driver for growth. Moreover, we are committed to the continuous enhancement of the Rewell digital platform, aiming to enrich user experience and drive customer engagement by offering expanded informational content and increasing value based on market needs, which may vary from market to market. Heritas: Diagnostics, Prognosis, & Monitoring Patients with a clinical condition often receive a generic diagnosis and treatment for their condition or disease. However, due to the genetic